Zimberelimab (AB122)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Note: Zimberelimab is approved in China, but does not appear to have a brand name at this time.

Mechanism of action

PD-1 inhibitor

Diseases for which it is used

History of changes in NPMA indication

  • 8/30/2021: Approved for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).

Also known as

  • Code name: AB122